New sleeping pill poised to hit US markets

May 21, 2013

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

But the experts warned of dangerous side effects at high doses—including residual sleepiness during the day and, in a small number of subjects, —according to their report posted Tuesday.

The FDA has convened a group of independent experts for Wednesday to make recommendations to the agency on whether to authorize the medication for the US market.

The FDA is not required to follow the recommendations of the panel, but generally does so.

The drug, Suvorexant, also known as MK-4305, is a new class of sleeping pill, which works by blocking "-promoting orexin neurons" from working, thus helping the body transition to sleep.

Merck has proposed a dose of 15 milligrams for people over 65 and 20 milligrams for those under 65, with doses up to twice as high recommended for those whose symptoms persist.

But the FDA noted clinical trials indicated a dose of just 10 milligrams was safe and effective, and it planned to ask the independent panel to consider recommending all patients start with this smaller dose and whether it should ask Merck to study if doses under 10 milligrams might also be effective.

In January, the FDA asked the pharmaceutical companies behind Ambien and other similar sleep aids to reduce their recommended dosages after studies showed an increased risk of and related car accidents.

The FDA notably required the companies to cut by half the recommended doses for some for women—whose bodies apparently metabolize the drugs more slowly.

Insomnia affects up to 30 percent of US adults, the FDA said.

According to analysts, Suvorexant could generate for Merck some $650 million in sales by 2018.

Explore further: FDA has safety concerns on Merck insomnia drug

Related Stories

FDA has safety concerns on Merck insomnia drug

May 20, 2013
Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

FDA: lower ambien's dose to prevent drowsy driving

May 15, 2013
(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard while performing ...

FDA reviewing Merck's experimental insomnia drug

November 8, 2012
(AP)—Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its experimental insomnia medication, suvorexant (SOO'vor-eks-ant).

FDA requires lower doses for sleep medications (Update)

January 10, 2013
(HealthDay)—The U.S. Food and Drug Administration announced Thursday that it is asking manufacturers of sleep medications containing zolpidem—including Ambien—to lower the recommended doses and to provide more safety ...

Is a better sleeping pill on the way?

April 3, 2013
(HealthDay)—A new class of sleep medications appears to help people fall asleep without causing grogginess the next day, researchers say.

Merck says FDA reviewing its ragweed allergy therapy

May 8, 2013
Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.